Literature DB >> 3300817

High dose busulfan/etoposide as a preparatory regimen for second bone marrow transplants in hematologic malignancies.

K G Blume, S J Forman.   

Abstract

Five patients with hematologic malignancies who had relapsed between seven months and eight years after their primary bone marrow transplants were prepared with high dose busulfan/etoposide for second marrow transplantations from the same donors who had provided the marrow for the primary transplants. The preparatory regimen was well tolerated. All patients engrafted and entered complete remission. Two patients are alive and in continued remission two and ten months after second transplant. One patient died with acute respiratory failure after two months and two patients relapsed again eight and 17 months after second marrow transplantation. The combination busulfan/etoposide may prove to be a suitable preparatory regimen for second bone marrow transplant attempts in selected patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3300817     DOI: 10.1007/BF00319642

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  11 in total

1.  A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.

Authors:  S J Forman; K G Blume; R A Krance; P J Miner; G E Metter; L R Hill; M R O'Donnell; A P Nademanee; D S Snyder
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

2.  Hyperfractionated total body irradiation for bone marrow transplantation: I. Early results in leukemia patients.

Authors:  B Shank; S Hopfan; J H Kim; F C Chu; E Grossbard; N Kapoor; D Kirkpatrick; R Dinsmore; L Simpson; A Reid; C Chui; R Mohan; D Finegan; R J O'Reilly
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-08       Impact factor: 7.038

3.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

4.  Experience with second marrow transplants.

Authors:  S E Wright; E D Thomas; C D Buckner; R A Clift; A Fefer; P E Neiman; R Storb
Journal:  Exp Hematol       Date:  1976-07       Impact factor: 3.084

5.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies.

Authors:  K G Blume; S J Forman; M R O'Donnell; J H Doroshow; R A Krance; A P Nademanee; D S Snyder; G M Schmidt; J L Fahey; G E Metter
Journal:  Blood       Date:  1987-04       Impact factor: 22.113

Review 6.  Karnofsky Memorial Lecture. Marrow transplantation for malignant diseases.

Authors:  E D Thomas
Journal:  J Clin Oncol       Date:  1983-09       Impact factor: 44.544

7.  Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis.

Authors:  T T Chang; S C Gulati; T C Chou; R Vega; L Gandola; S M Ibrahim; J Yopp; M Colvin; B D Clarkson
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

8.  Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia.

Authors:  K G Blume; E Beutler; K J Bross; R K Chillar; O B Ellington; J L Fahey; M J Farbstein; S J Forman; G M Schmidt; E P Scott; W E Spruce; M A Turner; J L Wolf
Journal:  N Engl J Med       Date:  1980-05-08       Impact factor: 91.245

9.  Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.

Authors:  G W Santos; P J Tutschka; R Brookmeyer; R Saral; W E Beschorner; W B Bias; H G Braine; W H Burns; G J Elfenbein; H Kaizer
Journal:  N Engl J Med       Date:  1983-12-01       Impact factor: 91.245

10.  Genetic markers in human bone marrow transplantation.

Authors:  K G Blume; E Beutler; K J Bross; G M Schmidt; W E Spruce; R L Teplitz
Journal:  Am J Hum Genet       Date:  1980-05       Impact factor: 11.025

View more
  2 in total

Review 1.  Etoposide and teniposide in the treatment of acute leukemia.

Authors:  M Björkholm
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

Review 2.  Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  George E Georges; Rainer Storb
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.